- Home
- GRNT vs CGEM Comparison
GRNT vs CGEM Comparison
Compare GRNT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | CGEM |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.8M | 794.7M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRNT | CGEM |
|---|---|---|
| Price | $5.54 | $13.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.11 |
| AVG Volume (30 Days) | ★ 861.5K | 702.8K |
| Earning Date | 03-05-2026 | 03-10-2026 |
| Dividend Yield | ★ 8.02% | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $450,306,000.00 | N/A |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $7.47 | $79.85 |
| P/E Ratio | $30.58 | ★ N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $4.18 | $5.68 |
| 52 Week High | $6.59 | $16.74 |
Technical Indicators
Market Signals| Indicator | GRNT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 44.57 |
| Support Level | $5.21 | $11.43 |
| Resistance Level | $5.85 | $13.21 |
| Average True Range (ATR) | 0.21 | 0.86 |
| MACD | 0.03 | -0.32 |
| Stochastic Oscillator | 95.53 | 16.70 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.